Literature DB >> 33657299

Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.

Delia Goletti1, Fabrizio Cantini1.   

Abstract

Entities:  

Year:  2021        PMID： 33657299     DOI： 10.1056/NEJMe2034982

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

Review 1.  Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19.

Authors:  Doris Loh; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

Review 2.  Pharmacological and non-pharmacological strategies in coronavirus disease 2019: A literature review.

Authors:  Francisco J González-Ruiz
Journal:  Ann Med Surg (Lond)       Date:  2022-05-08

Review 3.  Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?

Authors:  Ivan Zanoni
Journal:  Curr Opin Virol       Date:  2021-08-17       Impact factor: 7.090

4.  Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).

Authors:  Matteo Bassetti; Daniele Roberto Giacobbe; Paolo Bruzzi; Emanuela Barisione; Stefano Centanni; Nadia Castaldo; Silvia Corcione; Francesco Giuseppe De Rosa; Fabiano Di Marco; Andrea Gori; Andrea Gramegna; Guido Granata; Angelo Gratarola; Alberto Enrico Maraolo; Malgorzata Mikulska; Andrea Lombardi; Federico Pea; Nicola Petrosillo; Dejan Radovanovic; Pierachille Santus; Alessio Signori; Emanuela Sozio; Elena Tagliabue; Carlo Tascini; Carlo Vancheri; Antonio Vena; Pierluigi Viale; Francesco Blasi
Journal:  Infect Dis Ther       Date:  2021-07-30

5.  Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients.

Authors:  Raffaella Marocco; Anna Carraro; Maria Antonella Zingaropoli; Parni Nijhawan; Eeva Tortellini; Mariasilvia Guardiani; Fabio Mengoni; Paola Zuccalà; Valeria Belvisi; Blerta Kertusha; Alberico Parente; Cosmo Del Borgo; Vincenzo Vullo; Maria Rosa Ciardi; Claudio Maria Mastroianni; Miriam Lichtner
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 7.561

Review 6.  Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.

Authors:  Arbind Kumar; Aashish Sharma; Narendra Vijay Tirpude; Suresh Sharma; Yogendra S Padwad; Sanjay Kumar
Journal:  Inflammopharmacology       Date:  2022-01-20       Impact factor: 5.093

Review 7.  Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?

Authors:  Johnson M Liu; Jeffrey Chi
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-22

8.  Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.

Authors:  Tonino Alonzi; Alessandra Aiello; Linda Petrone; Saeid Najafi Fard; Manuela D'Eletto; Laura Falasca; Roberta Nardacci; Federica Rossin; Giovanni Delogu; Concetta Castilletti; Maria Rosaria Capobianchi; Giuseppe Ippolito; Mauro Piacentini; Delia Goletti
Journal:  Cells       Date:  2021-12-24       Impact factor: 6.600

9.  JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells.

Authors:  Hye Kyung Lee; Olive Jung; Lothar Hennighausen
Journal:  Commun Biol       Date:  2021-06-02

Review 10.  COVID-19: Zinc and Angiotensin-Converting Enzyme 2 (ACE2) Deficiencies as Determinants of Risk and Severity of Disease: A Narrative Review.

Authors:  Miklos P Salgo
Journal:  Infect Dis Ther       Date:  2021-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.